HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Haier Biomedical (688139.CH) - Just Been Included in the FTSE GEIS, Time to Follow

Beijing Wantai Biological (603392.CH) - After A 3839% Rally, Let's Look at Some Concerns

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

Luye Pharma (2186.HK) - Could the Magic of Hillhouse Last Long?

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

Jinxin Fertility (锦欣生殖) Placement - Setting up for Acquisitions

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Jinxin Fertility Group  / Equity Bottom-Up

<p>Since 2016, the number of new births in China has continued to decline, raising public debate on whether the population policy needs to be adjusted. The National Health Commission has made a clear response recently, saying that Northeast China "can explore" to take the lead in fully liberalizing birth restrictions, and <a href="https://www.smartkarma.com/entities/jinxin-fertility-group-ltd" target="_blank" data-smartkarma-citation="entities:28003:1" rel="noopener">Jinxin Fertility Co Ltd (1951 HK)</a>, a leading ARS provider in China and the United States, is undoubtedly one of the beneficiaries of related policy. Recently, Jinxin reached a record high of HK$23.65, with a current market value of about HK$57.8 billion, and the stock has been increased about 45% this year.</p>

Since 2016, the number of new births in China has continued to decline, raising public debate on whether the population policy needs to be adjusted. The National Health Commission has made a clear response recently, saying that Northeast China "can explore" to take the lead in fully liberalizing birth restrictions, and Jinxin Fertility Co Ltd (1951 HK), a leading ARS provider in China and the United States, is undoubtedly one of the beneficiaries of related policy. Recently, Jinxin reached a record high of HK$23.65, with a current market value of about HK$57.8 billion, and the stock has been increased about 45% this year.

Jinxin Fertility (1951.HK) - The New Policy, the Logic and the Risk Factors